Latest Breaking News On - Dementia due - Page 1 : comparemela.com

IGC Pharma : Announces Positive Interim Results for IGC-AD1 in - Form 8-K -April 05, 2024 at 11:36 am EDT

IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer s Agitation - Interim Data: Study Achieves Primary End Point Demonstrating.

United statesRam mukundaJanet vasquezRosalyn christianPharma incDrug administrationExchange commissionAnnounces positive interim resultsStatistically significant reductions comparedAgitation associatedDementia dueCohen mansfield agitation inventorySpecified interim resultsIllustrative brexpiprazole phaseArtificial intelligenceLooking statements

BioVie: Upcoming Phase 3 Readout In Alzheimer s May Create Significant Value (NASDAQ:BIVI)

BioVie: Upcoming Phase 3 Readout In Alzheimer s May Create Significant Value (NASDAQ:BIVI)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

Eli lillyTerren peizerCantor fitzgeraldAlzheimer research therapyCorporate presentationDementia dueFinding treatment effectsAlzheimer trialsDisease progression heterogeneitySales agreement

Brexpiprazole Demonstrates Clinically Meaningful Improvements for Agitation Due to Alzheimer Disease

Brexpiprazole Demonstrates Clinically Meaningful Improvements for Agitation Due to Alzheimer Disease
pharmacytimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmacytimes.com Daily Mail and Mail on Sunday newspapers.

Georget grossbergJohn krausOtsuka pharmaceutical development commercialization incInternational associationLundbeck pharmaceuticalsOtsuka pharmaceutical developmentCommercialization incBehavioral neuroscienceSaint louis university schoolMini mental state examinationCohen mansfield agitation inventoryPublishes complete resultsPositive phaseAgitation associatedDementia dueDementia related

JAMA Neurology Publishes Complete Results of Positive Phase 3 Study of REXULTI® (brexpiprazole) for

New efficacy data reported for pivotal Study 213 shows significant, clinically meaningful improvements in agitation symptoms.Agitation symptoms negatively impact functioning, disease progression, quality of life and care for about half of Alzheimer’s dementia patients – and are a consistent predictor of nursing home.

United statesJohn krausRobert murphyGeorget grossbergJohan luthmanLundbeck pharmaceuticalsDepartment of psychiatryOtsuka holdings co ltdCorporate communicationsOtsuka america pharmaceutical incLundbeck research developmentNational pregnancy registry for atypical antipsychoticsOtsuka pharmaceutical company ltdHealth canadaInternational psychogeriatric associationOtsuka pharmaceutical co ltd

Otsuka and Lundbeck Announce U S Food and Drug Administration (FDA) Approval of Supplemental New Drug Application (sNDA) for REXULTI® (brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer s Disease | Illinois

PRINCETON, N.J. & DEERFIELD, Ill. (BUSINESS WIRE) May 10, 2023

United statesStatesrobert murphyMakoto inoueDeborah dunsireStatesdyana lescohierStatesjeffrey gilbertInternational psychogeriatric associationDrug administrationOtsuka pharmaceutical development commercialization incOtsuka pharmaceutical company ltdOtsuka holdings co ltdOtsuka pharmaceutical co ltdMinistry of healthCorporate communicationsNational pregnancy registry for atypical antipsychoticsEuropean medicines agency